BURLINGTON, Mass. / Mar 08, 2023 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly"), a digital health company transforming care with handheld, whole-body ultrasound, today announced that it will participate in the 33rd Annual Oppenheimer Healthcare Conference taking place virtually on March 13-15, 2023. Heather Getz, Executive Vice President & Chief Financial Officer, Darius Shahida, Chief Strategy Officer & Chief Business Development Officer, and Dr. John Martin, Chief Medical Officer will present on March 14, 2023 at 10:40am Eastern Time.
A live webcast of the presentation will be available in the Events & Presentations section of the Butterfly Network investor website.
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011 and listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world's first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ can be purchased today by trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, North America and South America; to learn more about available countries, visit: butterflynetwork.com/choose-your-country. Butterfly iQ+ is a prescription device intended for trained healthcare professionals only.
Last Trade: | US$1.80 |
Daily Change: | 0.04 2.27 |
Daily Volume: | 1,915,940 |
Market Cap: | US$397.550M |
February 28, 2025 January 29, 2025 January 13, 2025 January 08, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load